Drugs were chosen based on their clinical use in thyroid cancer therapy, and included investigational agents being tested in clinical trials such as drugs targeting the RAS/RAF/MEK/ERK pathway (Fig. 5b). Here, MAP2K7 is linked to thyroid gland carcinoma.